{'fraction_non_alphanumeric': 0.028930817610062894, 'fraction_numerical': 0.022641509433962263, 'mean_word_length': 5.419354838709677, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combined radiation and hormonal therapy or dose escalation for men with unfavourable‐risk prostate cancer: an evidence‐based approach using a synthesis of randomized clinical trials

In 2008, ≈ 190 000 men in the USA will be diagnosed with prostate cancer, but only ≈ 29 000 will die from their disease [1]; most of these prostate cancer-specific deaths will be in those patients with advanced disease [2]. Although PSA screening has enabled physicians to detect prostate cancer at earlier stages, resulting in stage migration, there continues to be a significant number of men who initially present with localized but unfavourable disease, with resulting morbidity and mortality [3]. Therefore, it is imperative that clinicians optimize their therapeutic strategies, particularly for these men.